Table 4.
Change in medication use in 12 months prior to versus postinitiation of mepolizumab
| Medication | Premepolizumab mean-weighted average dispensings | Pre-SD | Postmepolizumab mean-weighted average dispensings | Post-SD | Per cent reduction (negative indicates increase) |
| Single controller medication | |||||
| Low ICS or medium-dose ICS | 0.74 | 3 | 0.71 | 3.3 | 5 |
| High-dose ICS | 0.61 | 2.8 | 0.67 | 3.4 | −10 |
| LAMA | 1.3 | 3.3 | 1.6 | 4.1 | −22 |
| LTRA | 3.3 | 3.8 | 3.5 | 4.3 | −4 |
| Oral corticosteroids (28+ days) | 1.5 | 3.3 | 1.6 | 3.7 | −5 |
| Combination | |||||
| ICS/LABA (any dose) | 2.7 | 3.3 | 2.8 | 3.8 | −4 |
| Low-dose ICS/LABA | 1.8 | 3.1 | 2 | 3.7 | −9 |
| Medium-dose or high-dose ICS/ LABA | 0.91 | 3.3 | 0.86 | 3.8 | 5 |
| Low-dose or medium-dose ICS/ LTRA | 0.34 | 2.2 | 0.33 | 2.6 | 3 |
| ICS/LTRA | |||||
| High-dose ICS/ LTRA | 0.29 | 2.1 | 0.31 | 2.6 | −7 |
| Biologics | |||||
| Omalizumab | 1.4 | 6.6 | 0.54 | 6.4 | 61 |
| Reslizumab | 0.001 | 0.71 | 0.028 | 3.6 | −4992 |
| Benralizumab | 0.001 | 1.4 | 0.075 | 2.5 | −6650 |
| Dupilumab | 0.004 | 2.1 | 0.036 | 3.7 | −712 |
| Rescue | |||||
| Oral corticosteroids (3–27 days) | 3.2 | 3.5 | 2.1 | 2.8 | 35% |
| SABA | 3.8 | 4.6 | 3.6 | 4.9 | 6% |
Paired measurements were not available due to aggregated nature of data.
ICS, inhaled corticosteroids; LABA, long-acting beta agonists; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonists; SABA, short-acting beta agonist.